User profiles for Andre Charlett
 | Andre CharlettDepartment Head, Public Health England Verified email at phe.gov.uk Cited by 21617 |
Comparison of Nine Commercially Available Clostridium difficile Toxin Detection Assays, a Real-Time PCR Assay for C. difficile tcdB, and a Glutamate …
K Eastwood, P Else, A Charlett… - Journal of clinical …, 2009 - Am Soc Microbiol
The continuing rise in the incidence of Clostridium difficile infection is a cause for concern,
with implications for patients and health care systems. Laboratory diagnosis largely relies on …
with implications for patients and health care systems. Laboratory diagnosis largely relies on …
Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B. 1.1. 529) and delta (B. 1.617. 2) variants in England: a cohort …
Background The omicron variant (B.1.1.529) of SARS-CoV-2 has demonstrated partial vaccine
escape and high transmissibility, with early studies indicating lower severity of infection …
escape and high transmissibility, with early studies indicating lower severity of infection …
Community transmission and viral load kinetics of the SARS-CoV-2 delta (B. 1.617. 2) variant in vaccinated and unvaccinated individuals in the UK: a prospective …
…, MG Whitfield, R Varro, A Charlett… - The lancet infectious …, 2022 - thelancet.com
Background The SARS-CoV-2 delta (B.1.617.2) variant is highly transmissible and spreading
globally, including in populations with high vaccination rates. We aimed to investigate …
globally, including in populations with high vaccination rates. We aimed to investigate …
Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B. 1.617. 2) compared with alpha (B. 1.1. 7) variants of concern: a cohort study
…, J Lopez-Bernal, E Gallagher, A Charlett… - The Lancet Infectious …, 2022 - thelancet.com
Background The SARS-CoV-2 delta (B.1.617.2) variant was first detected in England in March,
2021. It has since rapidly become the predominant lineage, owing to high transmissibility. …
2021. It has since rapidly become the predominant lineage, owing to high transmissibility. …
Protection against SARS-CoV-2 after Covid-19 vaccination and previous infection
…, CS Brown, T Brooks, J Islam, A Charlett… - … England Journal of …, 2022 - Mass Medical Soc
Background The duration and effectiveness of immunity from infection with and vaccination
against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are relevant to …
against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are relevant to …
SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study …
VJ Hall, S Foulkes, A Charlett, A Atti, EJM Monk… - The Lancet, 2021 - thelancet.com
Background Increased understanding of whether individuals who have recovered from
COVID-19 are protected from future SARS-CoV-2 infection is an urgent requirement. We aimed to …
COVID-19 are protected from future SARS-CoV-2 infection is an urgent requirement. We aimed to …
Duration of infectiousness and correlation with RT-PCR cycle threshold values in cases of COVID-19, England, January to May 2020
A Singanayagam, M Patel, A Charlett… - …, 2020 - eurosurveillance.org
Severe acute respiratory syndrome coronavirus 2 viral load in the upper respiratory tract
peaks around symptom onset and infectious virus persists for 10 days in mild-to-moderate …
peaks around symptom onset and infectious virus persists for 10 days in mild-to-moderate …
Comparison of diagnostic sensitivity and specificity of seven Cryptosporidium assays used in the UK
…, BM Campbell, N Crouch, A Charlett… - Journal of medical …, 2011 - microbiologyresearch.org
To compare the diagnostic sensitivity and specificity of seven Cryptosporidium diagnostic
assays used in the UK, results from 259 stool samples from patients with acute gastrointestinal …
assays used in the UK, results from 259 stool samples from patients with acute gastrointestinal …
Comparative transmission of SARS-CoV-2 Omicron (B. 1.1. 529) and Delta (B. 1.617. 2) variants and the impact of vaccination: national cohort study, England
…, J Lopez-Bernal, G Dabrera, A Charlett… - Epidemiology & …, 2023 - cambridge.org
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant (B.1.1.529)
rapidly replaced Delta (B.1.617.2) to become dominant in England. Our study …
rapidly replaced Delta (B.1.617.2) to become dominant in England. Our study …
Insidious Risk of Severe Mycobacterium chimaera Infection in Cardiac Surgery Patients
…, S Bhatt, A Skingsley, A Charlett… - Clinical infectious …, 2017 - academic.oup.com
Background. An urgent UK investigation was launched to assess risk of invasive
Mycobacterium chimaera infection in cardiothoracic surgery and a possible association with …
Mycobacterium chimaera infection in cardiothoracic surgery and a possible association with …
